Despite a few leaping tech names, small-cap stocks once again slunk behind the broad indices Wednesday. But BladeLogic ( BLOG), a data-center automation-software company, catapulted 45.2% to $24.69 after its initial public offering of 5 million shares, 3.94 million of which are being sold by the company itself. Underwriters have an option for another 750,000 shares. Supertex ( SUPX), a Sunnyvale, Calif., semiconductor firm, jumped 13.6% despite coming in just under top- and bottom-line expectations for the fiscal first quarter, and semiconductor-equipment maker Semitool ( SMTL) was higher after posting a small break-even loss for the quarter ended June 30 on revenue of $46.6 million. Thomson Financial's estimates had it losing 2 cents a share, and two analysts predicted sales of $45.5 million. Supertex shares were up $4.41 to $36.91 as Montana-based Semitool gained 13% to $10.20, each in support of the Russell 2000, which was up 0.2% to 813.07. The S&P SmallCap 600, which counts Supertex as a member, was up marginally at 426.99. GPC Biotech ( GPCB) was among Wednesday's worst losers overall, however, after a Food and Administration advisory panel unanimously recommended that the FDA wait for more information before approving its prostate-cancer drug satraplatin. Shares of the Germany-based company plummeted 34.6% to $13.32 as partner Spectrum Pharmaceuticals ( SPPI) slid 17.1% to $3.98. Pharmion ( PHRM), which has some commercialization rights to the drug, gave up 1.2% to $24.32.
Targeted Genetics ( TGEN) was another big health-care loser. Shares of the Seattle biotech company slid 20.5% to $2.09 after the FDA put development of its investigational inflammatory-arthritis therapy, tgAAC94, on clinical hold "as a precautionary measure ... due to the uncertainty of the cause of a serious adverse event that occurred in one subject." The compound had been in phase I/II testing. Away from health stocks, Jakks Pacific ( JAKK) was hurting after the Malibu, Calif., toy company whittled its second-quarter income down to $5 million, or 17 cents a share, from 22 cents a share last year. Wall Street had expected a year-over-year rise to 25 cents a share. Jakks stock was losing $4.52, or 15.1%, to $25.40. Meanwhile, France-based telecom company Wavecom ( WVCM) plunged more than 20% even though second-quarter income vaulted to $6.9 million (5 million euros), or 41 cents a share, compared with about a penny a share last year. Shares were losing $7.39 to $29.20.